Related Experiment Video
Updated: Dec 31, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Structure and regulation of human epithelial cell transforming 2 protein
Mengran Chen1,2,3, Han Pan1,2, Lingfei Sun2
1Ministry of Education Key Laboratory of Protein Science, Tsinghua University, Beijing 100084, China.
Abstract:
Epithelial cell transforming 2 (Ect2) protein activates Rho GTPases and controls cytokinesis and many other cellular processes. Dysregulation of Ect2 is associated with various cancers. Here, we report the crystal structure of human Ect2 and complementary mechanistic analyses. The data show the C-terminal PH domain of Ect2 folds back and blocks the canonical RhoA-binding site at the catalytic center of the DH domain, providing a mechanism of Ect2 autoinhibition. Ect2 is activated by binding of GTP-bound RhoA to the PH domain, which suggests an allosteric mechanism of Ect2 activation and a positive-feedback loop reinforcing RhoA signaling. This bimodal RhoA binding of Ect2 is unusual and was confirmed with Förster resonance energy transfer (FRET) and hydrogen-deuterium exchange mass spectrometry (HDX-MS) analyses. Several recurrent cancer-associated mutations map to the catalytic and regulatory interfaces, and dysregulate Ect2 in vitro and in vivo. Together, our findings provide mechanistic insights into Ect2 regulation in normal cells and under disease conditions.
Insights
Epithelial cell transforming 2 (Ect2) protein regulates cell division and is implicated in cancer. We discovered Ect2
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Epithelial cell transforming 2 (Ect2) protein is a key regulator of Rho GTPases, essential for cytokinesis and other cellular functions.
- Dysregulation of Ect2 is frequently observed in various types of cancer, highlighting its role in tumorigenesis.
Purpose of the Study:
- To elucidate the structural and mechanistic basis of Ect2 regulation.
- To investigate how cancer-associated mutations affect Ect2 function and regulation.
Main Methods:
- X-ray crystallography to determine the structure of human Ect2.
- Biochemical assays, including Förster resonance energy transfer (FRET) and hydrogen-deuterium exchange mass spectrometry (HDX-MS), to analyze Ect2-RhoA interactions.
- In vitro and in vivo studies to assess the impact of cancer mutations on Ect2 activity.
Main Results:
- The crystal structure reveals that the C-terminal PH domain of Ect2 autoinhibits the enzyme by blocking the RhoA-binding site.
- Ect2 activation occurs through an allosteric mechanism involving GTP-bound RhoA binding to the PH domain, creating a positive-feedback loop for RhoA signaling.
- Recurrent cancer mutations identified at regulatory and catalytic interfaces were shown to dysregulate Ect2 activity.
Conclusions:
- Ect2 autoinhibition by its PH domain provides a novel regulatory mechanism.
- The allosteric activation by RhoA suggests a sophisticated feedback loop in RhoA signaling.
- Understanding Ect2 regulation and the impact of cancer mutations offers insights into therapeutic strategies for Ect2-driven cancers.
Related Concept Videos
TGF - β Signaling Pathway
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Abnormal Proliferation
Negative Regulator Molecules
Mitogens and the Cell Cycle
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

